CD19 and neoplasm: The analysis revealed a significant decrease in proliferative activity of H522(CD19+) PC-3M(CD19+), A431(CD19+), and MDA-MB-231(CD19+) tumor cell lines after adding CAR-T cells compared to control non-modified H522 and PC-3M cells.